Fig. 4: Re-expression of LCN2 rescues ferroptosis resistance in Nupr1-deficient cells.

a qPCR analysis of Lcn2 mRNA in indicated mPDAC cells following treatment with erastin (10 µM) or RSL3 (1 µM) for 24 h (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). b Cell viability in indicated mPDAC cells following treatment with erastin or RSL3 for 24 h (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). c–f Indicated mPDAC cells were treated with erastin (10 µM) or RSL3 (1 µM) for 24 h, and then intracellular Fe²⁺ (c), intracellular MDA (d), intracellular 8-OHdG (e), and extracellular HMGB1 were assayed (n = 3 well/group, two-way ANOVA with Tukey’s multiple comparisons test on all pairwise combinations). Data in a–f are presented as mean ± SD. The results in a–f are representative of those from 2 to 3 independent experiments with three technical replicates each.